My ePortfolio Register   
Repurposing Drugs in Oncology - Nitroglycerin as an anti-cancer agent

Repurposing Drugs in Oncology - Nitroglycerin as an anti-cancer agent

en English

Complete this module today and earn yourself 1 CME Point.

Proceed to module  Shortlist  Rate Module  Share

en English

Summary This e-learning module has been developed for clinicians in partnership with ecancer and ReDO

Repurposing Drugs in Oncology (ReDO)—nitroglycerin as an anti-cancer agent. This module has been developed in partnership with ecancer and ReDO to enhance a learner's understanding of the issues involved in drug repurposing. It is based on an article published in ecancer.

This module was published in May 2017

Target Audience


Learning Objectives

By the end of this module you should be able to:

  • Identify that repurposing is efficient and cost-effective, assuming we can prove efficacy
  • Be familiar with the many cancer related mechanisms of action that nitroglycerin has
  • Understand that reducing hypoxia with nitroglycerin can increase the therapeutic effect of existing chemo and chemoradiation protocols
  • Understand that additional clinical trials of nitroglycerin are warranted

The learner will receive 1 EACCME point upon passing the assessment.

You may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits. Information on the process to convert EACCME credit to AMA credit can be found at

IT Requirements

This module requires the learner to have a good, stable internet connection and can run on Internet Explorer 7 and above, Mozilla Firefox, Google Chrome and Opera on either Windows or MacOS. Flash Add-on is also required to run this module.

If you are viewing this module on an iPad (through a browser), please download the free Articulate Mobile Player beforehand. Other tablet devices may not be compatible - please check for Flash compatibility.

If you are experiencing technical difficulties, please contact and we will get back to you as soon as possible.

Disclosure Policy

ecancer and Dr Pan Pantziarka, PhD, Anticancer Fund, Strombeek-Bever, Belgium have no actual or potential conflict of interest whatsoever which impinges on the making, peer reviewing and dissemination of this Re-DO e-learning module. We have no disclosures to report in relation to this project.

Proceed to Module
Proceed to module  Shortlist  Rate Module

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence